{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T08:57:23Z","timestamp":1775897843692,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Takeda Oy"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00277-024-06101-3","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T03:52:14Z","timestamp":1734321134000},"page":"2373-2385","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A real-world study on the impact of infection load on mortality in multiple myeloma patients in Finland"],"prefix":"10.1007","volume":"104","author":[{"given":"Anna","family":"Anttalainen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Essi","family":"Havula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Kysenius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iiro","family":"Toppila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatu","family":"Miettinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariann","family":"Lassenius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raija","family":"Silvennoinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anu","family":"Partanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mervi","family":"Putkonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"6101_CR1","doi-asserted-by":"publisher","first-page":"e1406","DOI":"10.1634\/theoncologist.2020-0141","volume":"25","author":"H Ludwig","year":"2020","unstructured":"Ludwig H, Novis Durie S, Meckl A et al (2020) Multiple myeloma incidence and Mortality around the Globe; interrelations between Health Access and Quality, Economic resources, and patient empowerment. Oncologist 25:e1406\u2013e1413. https:\/\/doi.org\/10.1634\/theoncologist.2020-0141","journal-title":"Oncologist"},{"key":"6101_CR2","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364:1046\u20131060. https:\/\/doi.org\/10.1056\/NEJMra1011442","journal-title":"N Engl J Med"},{"key":"6101_CR3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s12885-023-10787-5","volume":"23","author":"C Eisfeld","year":"2023","unstructured":"Eisfeld C, Kaj\u00fcter H, M\u00f6ller L et al (2023) Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany. BMC Cancer 23:317. https:\/\/doi.org\/10.1186\/s12885-023-10787-5","journal-title":"BMC Cancer"},{"key":"6101_CR4","doi-asserted-by":"publisher","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","volume":"23","author":"BM Augustson","year":"2005","unstructured":"Augustson BM, Begum G, Dunn JA et al (2005) Early Mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002\u2014Medical Research Council Adult Leukaemia Working Party. JCO 23:9219\u20139226. https:\/\/doi.org\/10.1200\/JCO.2005.03.2086","journal-title":"JCO"},{"key":"6101_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3324\/haematol.2014.107714","volume":"100","author":"C Blimark","year":"2015","unstructured":"Blimark C, Holmberg E, Mellqvist U-H et al (2015) Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica 100:107\u2013113. https:\/\/doi.org\/10.3324\/haematol.2014.107714","journal-title":"Haematologica"},{"key":"6101_CR6","doi-asserted-by":"publisher","unstructured":"Blimark CH, Carlson K, Day C, Haematologica et al (2024) https:\/\/doi.org\/10.3324\/haematol.2024.285645","DOI":"10.3324\/haematol.2024.285645"},{"key":"6101_CR7","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/S0268-960X(10)70004-7","volume":"24","author":"F Davies","year":"2010","unstructured":"Davies F, Baz R (2010) Lenalidomide mode of action: linking bench and clinical findings. Blood Rev 24:S13\u2013S19. https:\/\/doi.org\/10.1016\/S0268-960X(10)70004-7","journal-title":"Blood Rev"},{"key":"6101_CR8","doi-asserted-by":"publisher","first-page":"46593","DOI":"10.18632\/oncotarget.16235","volume":"8","author":"L Ying","year":"2017","unstructured":"Ying L, YinHui T, Yunliang Z, Sun H (2017) Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis. Oncotarget 8:46593\u201346600. https:\/\/doi.org\/10.18632\/oncotarget.16235","journal-title":"Oncotarget"},{"key":"6101_CR9","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487\u20132498. https:\/\/doi.org\/10.1056\/NEJMoa043445","journal-title":"N Engl J Med"},{"key":"6101_CR10","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1086\/605664","volume":"49","author":"M Nucci","year":"2009","unstructured":"Nucci M, Anaissie E (2009) Infections in patients with multiple myeloma in the era of high-dose therapy and Novel agents. CLIN INFECT DIS 49:1211\u20131225. https:\/\/doi.org\/10.1086\/605664","journal-title":"CLIN INFECT DIS"},{"key":"6101_CR11","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1186\/s12885-021-08451-x","volume":"21","author":"N Balmaceda","year":"2021","unstructured":"Balmaceda N, Aziz M, Chandrasekar VT et al (2021) Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019. BMC Cancer 21:730. https:\/\/doi.org\/10.1186\/s12885-021-08451-x","journal-title":"BMC Cancer"},{"key":"6101_CR12","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1097\/HS9.0000000000000163","volume":"3","author":"M Mateos","year":"2019","unstructured":"Mateos M, Ludwig H, Bazarbachi A et al (2019) Insights on multiple myeloma treatment strategies. HemaSphere 3:e163. https:\/\/doi.org\/10.1097\/HS9.0000000000000163","journal-title":"HemaSphere"},{"key":"6101_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A et al (2015) Elotuzumab Therapy for relapsed or refractory multiple myeloma. N Engl J Med 373:621\u2013631. https:\/\/doi.org\/10.1056\/NEJMoa1505654","journal-title":"N Engl J Med"},{"key":"6101_CR14","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/ejh.13597","volume":"106","author":"IS Sverrisd\u00f3ttir","year":"2021","unstructured":"Sverrisd\u00f3ttir IS, R\u00f6gnvaldsson S, Thorsteinsdottir S et al (2021) Comorbidities in multiple myeloma and implications on survival: a population-based study. Eur J Haematol 106:774\u2013782. https:\/\/doi.org\/10.1111\/ejh.13597","journal-title":"Eur J Haematol"},{"key":"6101_CR15","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1186\/s12879-020-05412-w","volume":"20","author":"C Lin","year":"2020","unstructured":"Lin C, Shen H, Zhou S et al (2020) Assessment of infection in newly diagnosed multiple myeloma patients: risk factors and main characteristics. BMC Infect Dis 20:699. https:\/\/doi.org\/10.1186\/s12879-020-05412-w","journal-title":"BMC Infect Dis"},{"key":"6101_CR16","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","volume":"9","author":"NS Raje","year":"2022","unstructured":"Raje NS, Anaissie E, Kumar SK et al (2022) Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol 9:e143\u2013e161. https:\/\/doi.org\/10.1016\/S2352-3026(21)00283-0","journal-title":"Lancet Haematol"},{"key":"6101_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2016.07.025","volume":"67","author":"BW Teh","year":"2016","unstructured":"Teh BW, Harrison SJ, Worth LJ et al (2016) Infection risk with immunomodulatory and proteasome inhibitor\u2013based therapies across treatment phases for multiple myeloma: a systematic review and meta-analysis. Eur J Cancer 67:21\u201337. https:\/\/doi.org\/10.1016\/j.ejca.2016.07.025","journal-title":"Eur J Cancer"},{"key":"6101_CR18","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.3390\/jcm11123541","volume":"11","author":"A Waszczuk-Gajda","year":"2022","unstructured":"Waszczuk-Gajda A, Penack O, Sbianchi G et al (2022) Complications of autologous stem cell transplantation in multiple myeloma: results from the CALM Study. JCM 11:3541. https:\/\/doi.org\/10.3390\/jcm11123541","journal-title":"JCM"},{"key":"6101_CR19","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538\u2013e548. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06101-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06101-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06101-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T03:13:49Z","timestamp":1746414829000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06101-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["6101"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06101-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"assertion":[{"value":"20 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AA, EH, KK, IT, and MIL are employees of Medaffcon Oy. TM was an employee of Takeda Finland and Medaffcon Oy. RS has received research funding, administered by Hospital Science Centers, from Amgen, BMS, Celgene, Janssen-Cilag and Takeda and honoraria from the same companies (Advisory Board and presentations).AP reports honoraria from Behring and Abbvie and has participated in Scientific Advisory Board meetings organized by Abbvie, Janssen-Cilag, Novartis, Pfizer and Takeda. MP has received honoraria from Amgen, Celgene, Janssen-Cilag and Takeda (Advisory Board and presentations).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by Findata, permission THL\/3276\/14.02.00\/2021 and Statistics Finland, permission TK\/1449\/07.03.00\/2022, in accordance with the act on the secondary use of health and welfare data in Finland.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval\u00a0"}}]}}